BeyondSpring
OverviewSuggest Edit
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programs.
| Type | Public | |
| Founded | 2010 | |
| HQ | New York, NY, US | Map |
| Website | beyondspringpharma.com | |
| Employee Ratings | More |
Recent NewsAll News
- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
- BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
- BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
- BeyondSpring to Present at Two Upcoming Scientific Conferences in December
Key People/Management at BeyondSpring
Lan Huang
Co-Founder, Chairman & Chief Executive Officer
Ramon Mohanlal
EVP, Research and Development, Chief Medical Officer
Rich Daly
Chief Operating Officer
Edward Dongheng Liu
Chief Financial Officer, China
Elizabeth Czerepak
Chief Financial Officer
Gordon Schooley
Chief Regulatory Officer
BeyondSpring Office Locations
BeyondSpring has an office in New York
New York, NY, US (HQ)
28 Liberty St 39th Floor
BeyondSpring Financials and Metrics
BeyondSpring Revenue
| USD | |
|---|---|
Net income (FY, 2019) | (40.3m) |
EBIT (FY, 2019) | (40.3m) |
Market capitalization (6-Jan-2021) | 478.3m |
Closing stock price (6-Jan-2021) | 12.2 |
Cash (31-Dec-2019) | 35.9m |
EV | 446.3m |
BeyondSpring's current market capitalization is $478.3 m.
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.0m | 2.8m | 3.3m | 728.0k | 1.4m | 1.5m | 1.6m | 2.1m | 2.5m |
R&D expense | 46.7m | 12.2m | 15.3m | 14.1m | 11.0m | 14.1m | 6.3m | 5.2m | 7.2m |
Operating expense total | 47.8m | 15.0m | 18.6m | 14.8m | 12.4m | 15.7m | 8.0m | 7.3m | 9.7m |
EBIT | (47.8m) | (15.0m) | (18.6m) | (14.8m) | (12.4m) | (15.7m) | (7.7m) | (7.3m) | (9.7m) |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 54.6m | 49.0m | 37.7m | 18.4m | 19.4m | 12.8m | 2.0m | 674.0k | 24.7k |
Prepaid Expenses | 131.0k | 338.0k | 236.0k | 284.0k | 525.0k | 473.0k | 150.0k | 167.0k | 362.0 |
Current Assets | 55.7m | 50.8m | 43.2m | 23.3m | 24.8m | 15.2m | 3.6m | 2.0m | 30.2k |
PP&E | 88.0k | 87.0k | 126.0k | 124.0k | 116.0k | 191.0k | 263.0k | 237.0k | 217.0 |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2019 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 47.7m | (62.6m) | (80.1m) | (14.1m) | (26.9m) | (42.8m) | (7.8m) | (15.4m) | (25.3m) |
Depreciation and Amortization | 6.0k | 13.0k | 22.0k | 12.0k | 20.0k | 29.0k | 23.0k | 41.0k | 61.0k |
Accounts Payable | 568.0k | 1.6m | 581.0k | 1.0m | (575.0k) | (18.0k) | (620.0k) | (1.1m) | (7.6m) |
Cash From Operating Activities | (5.3m) | (10.4m) | (18.6m) | (8.9m) | (22.0m) | (31.6m) | (5.1m) | (13.1m) | (35.5m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | 1.2 x |
BeyondSpring Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Beijing Wanchun Pharmaceutical Technology Ltd. | ||
| BeyondSpring (HK) Limited | ||
| BeyondSpring LTD. | ||
| BeyondSpring Pharmaceuticals Inc. | ||
| BeyondSpring Pharmaceuticals Australia PTY | ||
| SEED | ||
| SEED Technology | ||
| Wanchun Biotechnology Limited | ||
| Wanchun Biotechnology (Shenzhen) Ltd. | ||
| Wanchunbulin |
BeyondSpring Cybersecurity Score
BeyondSpring Online and Social Media Presence
109 Twitter followers
BeyondSpring has 109 Twitter Followers. The number of followers has increased 10.3% month over month and increased 21.4% quarter over quarter
BeyondSpring's Trends
Twitter Engagement Stats for @BeyondSpringInc
34
Tweets
1
Following
109
Followers
7
Tweets last 30 days
0.9
Avg. likes per Tweet
57.1%
Tweets with engagement
BeyondSpring News and Updates
December 29, 2020
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. …
December 17, 2020
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide th…
December 10, 2020
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone
November 25, 2020
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT032…
November 23, 2020
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that man…
November 17, 2020
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
- Announced SEED Therapeutics Inc.(“SEED”)’s collaboration with Eli Lilly and Company(“Lilly”)
BeyondSpring Blogs
December 10, 2019
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer
December 09, 2019
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
Content Import
Mon, 12/09/2019 - 08:01
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marr…
November 11, 2019
BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019
Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 NEW YORK , Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology
November 06, 2019
BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources,
October 25, 2019
BeyondSpring Announces Pricing of Ordinary Shares
NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its
October 24, 2019
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an
BeyondSpring Frequently Asked Questions
When was BeyondSpring founded?
BeyondSpring was founded in 2010.
Who are BeyondSpring key executives?
BeyondSpring's key executives are Lan Huang, Ramon Mohanlal and Rich Daly.
How many employees does BeyondSpring have?
BeyondSpring has 61 employees.
Who are BeyondSpring competitors?
Competitors of BeyondSpring include Omeros, Athersys and Otonomy.
Where is BeyondSpring headquarters?
BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.
Where are BeyondSpring offices?
BeyondSpring has an office in New York.
How many offices does BeyondSpring have?
BeyondSpring has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies